Scarica l'app Stockscreener
614.79
3.06%
18.25
Dopo l'orario di chiusura:
616.00
1.21
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
What Does Regeneron's Purchase of 23andMe Mean for Privacy? - GovInfoSecurity
23andMe sale: What will happen to the DNA data under Regeneron Pharmaceuticals - Deseret News
Regeneron Pharmaceuticals (NasdaqGS:REGN) Partners With Viz.ai For AI-Powered COPD Solutions - simplywall.st
Regeneron in Deal to Acquire 23andMe for $256M - Contract Pharma
Regeneron Pledges Privacy Protection in $256M Bid for 23andMe - Dark Reading
Regeneron to acquire 23andMe for $256M, plans to continue consumer genetics services - MassDevice
Regeneron to Buy 23andMe for $256M Amid Growing Data Privacy Concerns - GBHackers News
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research - Zacks Investment Research
What Regeneron’s $256M Purchase of 23andMe Means for Your DNA Data - cnynews.com
23andMe's sale to Regeneron doesn't include $400M Lemonaid acquisition, CEO Anne Wojcicki also bidBizwomen - The Business Journals
23andMe and its customers’ genetic data bought by a pharmaceutical org - Malwarebytes
Pharmaceutical company Regeneron buying 23andMe. Here's what to know. - Houston Chronicle
Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD) - BioSpace
Regeneron Pharmaceuticals to buy 23andMe for $256M - ABC News
2,000 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Tang Capital Management LLC - MarketBeat
5,849 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Tema Etfs LLC - MarketBeat
Regeneron to acquire 23andMe for US$256m after bankruptcy, aims to leverage genetic data - Malay Mail
Who owns your DNA now? Regeneron acquires 23andMe amid privacy concerns - Tech Funding News
Bankrupt DNA testing company 23andMe to be acquired by Regeneron for $256 million - Times of India
Regeneron Buys 23andMe for $256M After Bankruptcy - Finance Monthly
23andMe to Be Acquired by Regeneron After Bankruptcy Filing - The Cyber Express
23andMe and its customers’ data sold to US pharma giant - Silicon Republic
Regeneron to buy 23andMe out of bankruptcy for $256 million - The Hindu
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
OMERS ADMINISTRATION Corp Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bankrupt 23andMe sold for $256M—Who owns 15M DNA profiles now? - NewsBytes
Genetic data will be safeguarded with 23andMe sale, drugmaker vows - The Washington Post
23andMe customer data will be used for drug research following acquisition, Regeneron says - Cybernews
Pharma giant Regeneron to buy genetics firm 23andMe for $256m - Tech in Asia
Regeneron acquires bankrupt 23andMe for 356 billion won amid data breach fallout - Chosunbiz
Bankrupt DNA Company 23andMe Expected to Be Purchased for $256M: What Users Need to Know About Their Privacy - MSN
Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services - HIT Consultant
23andMe Purchase Will Let Regeneron Scale Drug Development - insights.citeline.com
Regeneron To Buy 23andMe For $256M After Bankruptcy: Here's What To Know - Blavity News
23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron's Gene-Based Drug R&D Efforts - MedCity News
What's not included in the 23andMe deal, and who else was bidding - The Business Journals
23andMe Finds $256M Buyer in Regeneron After Chapter 11 Filing - Athletech News
Regeneron Acquires 23andMe for $256 Million, Expanding Its Genetic Data and Innovation Footprint - WebProNews
23andMe To Be Acquired By Tarrytown-Based Regeneron For $256M - Patch
Nuveen Asset Management LLC Sells 211,009 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million - MSN
Mufg Securities Americas Inc. Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Now we know who's getting 23andMe's DNA data. Meet Regeneron Pharmaceuticals. - Mashable
23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million - The New York Times
Biotechnology company Regeneron buying 23andMe for $256 million - The Journal Gazette
Regeneron plans to buy 23andme from bankruptcy for $256M - BioWorld MedTech
Regeneron Sees 23andMe Buy As Complement To Genetics Platform - insights.citeline.com
Regeneron Pharmaceuticals to buy 23andMe for over $250 million - wng.org
23andMe to be acquired by NY-based Regeneron in $256 million deal - KTVU
Regeneron agrees to purchase bankrupt 23andMe, protect data - CFO Dive
23andMe assets being sold to Regeneron Pharma for $256M - MSN
Wachtell-Led Regeneron To Buy 23andMe, Gaining User Data - Law360
23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction - Investor's Business Daily
Bankrupt 23andMe Just Sold Off All Your DNA Data - futurism.com
Why Regeneron is buying 23andMe - Endpoints News
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal - Yahoo Finance
Focus Partners Wealth Purchases 6,213 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron acquires bankrupt 23andMe, pledges ethical use of genetic data - TradingView
Struggling DNA testing firm 23andMe to be bought for $256m - BBC
Regeneron in $256M deal to acquire human genetics and bio company - Westfair Communications
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data - Reuters
2.96%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):